Literature DB >> 7567117

[In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria].

S Bland1, A Sedallian, G Grollier, F Mory, I Houcke, L Dubreuil.   

Abstract

During 1994, the in vitro antibiotic susceptibility of 306 anaerobic bacteria was performed in 4 hospitals, by the reference agar dilution method. Among the 129 B. fragilis group strains, only two B. fragilis strains were resistant to the three carbapenems and all beta-lactams, even combined with beta-lactamase-inhibitors while metronidazole resistance could not be detected. Evolution in antibiotic resistance rates could be assessed only for piperacillin whose resistance rates increased to 20%. beta-lactamase production was detected respectively for 27% of Prevotella and 17% of Fusobacterium strains. No beta-lactamase activity was seen among Gram positive anaerobes. On the whole anaerobic strains resistance rates were: biapenem, imipenem, meropenem and piperacillin-tazobactam 0.7, amoxicillin-clavulanic acid or metronidazole 2, piperacillin 11.3, amoxicillin 31%, respectively. The three carbapenems demonstrated a good in vitro activity against most anaerobes with few differences between them.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567117

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.

Authors:  L Dubreuil; I Houcke; Y Mouton; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  Susceptibility testing of anaerobic bacteria: evaluation of the redesigned (Version 96) bioMérieux ATB ANA device.

Authors:  L Dubreuil; I Houcke; E Singer
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

Review 3.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.